SCHEMBL5832283

SCHEMBL5832283

CCCc1ccc(S(=O)(=O)Nc2nc(-c3ccc(NC(C)=O)cc3)ns2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.51
HSD17B10 Q99714 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 3/20 0.48
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
USP36 Q9P275 1/20 0.46
CA12 O43570 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831270 0.85 USP36 (0.62) AKT1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6934136 0.84 MEN1 (0.40) AKT1HSD17B10MEN1KMT2AMAPT
SCHEMBL5831430 0.84 USP36 (0.52) AKT1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL5832153 0.82 AKT1 (0.65) AKT1HSD17B10MEN1KMT2AMAPT
SCHEMBL2763159 0.82 MAPT (0.71) AKT1MEN1KMT2AMAPTPOLB
SCHEMBL6612133 0.77 POLB (0.49) AKT1MEN1KMT2AMAPTPOLB
SCHEMBL5832273 0.77 SMN1; SMN2 (0.47) AKT1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL5832095 0.76 ATM (0.62) AKT1MEN1KMT2AMAPTPOLB
SCHEMBL5831228 0.76 MEN1 (0.59) AKT1HSD17B10MEN1KMT2AMAPT
SCHEMBL5831678 0.76 AKT1 (0.44) AKT1MEN1KMT2ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 AKT1 2974/4885HSD17B10 23/4885MEN1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.